Insights

Gathering insights about Lumos…

Similar companies to Lumos

Lumos Tech Stack

Lumos uses 8 technology products and services including Linkedin Insight Tag, LottieFiles, Emotion, and more. Explore Lumos's tech stack below.

Linkedin Insight Tag
Analytics
LottieFiles
Design
Emotion
Javascript Frameworks
Qualified
Live Chat
ServiceNow
Miscellaneous
Java
Programming Languages
TypeScript
Programming Languages
HTTP/3
Web & Portal Technology

Media & News

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma's shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right (“CVR”) for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets that occur within 18 months of closing or certain sales, license or similar revenue-generating agreements entered into within 18 months of closing and that are related to Lumos Pharma's legacy products other than LUM-201. There can be no assurance any payments will be made with respect to the CVRs. The purchase price of $4.25 per share represents a total equity value of approximately $38 million, a premium of 7.6% to Lumos Pharma's closing share price of $3.95 on October 22, 2024, and a premium of 10.5% to Lumos Pharma's 30-trading-day volume weighted average price as of October 22, 2024.
Dec 12, 2024 | www.globenewswire.com
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Lumos Pharma Inc. ( NYSE: LUMO ) , relating to its proposed merger with Double Point Ventures LLC. Under the terms of the agreement, Double Point Ventures will acquire Lumos Pharma's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable unsecured Contingent Value Right per share payable on achievement of certain milestones.
Nov 06, 2024 | www.globenewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed acquisition of the company by Double Point Ventures LLC. Stockholders will receive $4.25 and one contingent value right for each share of Lumos Pharma stock that they hold.
Oct 23, 2024 | www.prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Martin Midstream Partners L.P. (NASDAQ: MMLP)'s sale to Martin Resource Management Corporation for $4.02 per common unit.
Oct 23, 2024 | www.prnewswire.com
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lumos Pharma, Inc. (NASDAQ: LUMO) to Double Point Ventures LLC for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right per share payable on achievement of certain milestones, is fair to Lumos shareholders. Halper Sadeh encourages Lumos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.
Oct 23, 2024 | www.businesswire.com
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.
Sep 25, 2024 | www.globenewswire.com
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th.
Aug 15, 2024 | www.globenewswire.com

Lumos's Email Address Formats

Lumos uses at least 1 format(s):

Lumos Email Formats	Example	Percentage
First@lumos.com	John@lumos.com	76%
First.Last@lumos.com	John.Doe@lumos.com	17%
Last@lumos.com	Doe@lumos.com	6%
FirstLast@lumos.com	JohnDoe@lumos.com	1%

Frequently Asked Questions

Where is Lumos's headquarters located?

Lumos's main headquarters is located at Moreno Valley, California United States. The company has employees across 5 continents, including North AmericaAfricaAsia.

What is Lumos's stock symbol?

Lumos is a publicly traded company; the company's stock symbol is LUMO.

What is Lumos's official website and social media links?

Lumos's official website is lumos.com and has social profiles on LinkedIn Crunchbase.

What is Lumos's NAICS code?

Lumos's NAICS code is 5112 - Software Publishers.

How many employees does Lumos have currently?

As of April 2026, Lumos has approximately 156 employees across 5 continents, including North AmericaAfricaAsia. Key team members include Chief Executive Officer: G. M.Vice President Of Channels And Partnerships: B. B.Head Of Demand Generation: T. M.. Explore Lumos's employee directory with LeadIQ.

What industry does Lumos belong to?

Lumos operates in the Software Development industry.

What technology does Lumos use?

Lumos's tech stack includes Linkedin Insight TagLottieFilesEmotionQualifiedServiceNowJavaTypeScriptHTTP/3.

What is Lumos's email format?

Lumos's email format typically follows the pattern of First@lumos.com. Find more Lumos email formats with LeadIQ.

How much funding has Lumos raised to date?

As of April 2026, Lumos has raised $35M in funding. The last funding round occurred on May 23, 2024 for $35M.

When was Lumos founded?

Lumos was founded in 2020.

Lumos

Q: What is Lumos's official website and social media links?

Lumos's official website is lumos.com. Lumos has social profiles on LinkedIn.

Q: How many employees does Lumos have currently?

Lumos has approximately 156 employees.

Q: What technology does Lumos use?

Lumos's tech stack includes Zendesk, HubSpot, jQuery, HSTS, Metabase.

Q: What is Lumos's NAICS code?

Lumos's NAICS code is 5112 (Software Publishers).

Software DevelopmentCalifornia, United States51-200 Employees

Lumos is the first Autonomous Identity platform to automatically discover and manage access across all your apps. Instead of being overwhelmed by the sprawl of apps and access, Lumos empowers organizations with one unified solution that controls access on auto-pilot. With Lumos, gain full visibility, enhance security, and boost productivity — all in one platform. Trusted by hundreds of Fortune 500 and emerging companies including Pinterest, Github, and Roku, Lumos powers millions of access requests across global companies.

Company Overview

Headquarters: Moreno Valley, California United States
Website: lumos.com
Stock Symbol: LUMO
NAICS Code: 5112 - Software Publishers
Founded: 2020
Employees: 51-200

Media & News

Funding & Financials

$35M
Lumos has raised a total of $35M of funding over 2 rounds. Their latest funding round was raised on May 23, 2024 in the amount of $35M.
$100M$250M
Lumos's revenue is estimated to be in the range of $100M$250M

Funding & Financials

$35M
Lumos has raised a total of $35M of funding over 2 rounds. Their latest funding round was raised on May 23, 2024 in the amount of $35M.
$100M$250M
Lumos's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Lumos

Imagine Learning

PowerSchool

Achieve3000

Cognia

Curriculum Associates

Edmentum

Khan Academy

Pearson

Study.com

Renaissance Learning

IXL Learning

MobyMax

Amplify

Lumos Tech Stack

Media & News

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders

LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Lumos's Email Address Formats

Frequently Asked Questions

Where is Lumos's headquarters located?

What is Lumos's stock symbol?

What is Lumos's official website and social media links?

What is Lumos's NAICS code?

How many employees does Lumos have currently?

What industry does Lumos belong to?

What technology does Lumos use?

What is Lumos's email format?

How much funding has Lumos raised to date?

When was Lumos founded?

Lumos

Company Overview

Media & News

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?